Format

Send to

Choose Destination
Clin Infect Dis. 2017 Aug 1;65(3):522-525. doi: 10.1093/cid/cix341.

The Cost of Not Retesting: Human Immunodeficiency Virus Misdiagnosis in the Antiretroviral Therapy "Test-and-Offer" Era.

Author information

1
Department of Infectious Disease Epidemiology, Imperial College London, United Kingdom.
2
HIV Department, World Health Organization, Geneva, Switzerland.
3
Biomedical Research and Training Institute, Harare, Zimbabwe.

Abstract

We compared estimated costs of retesting human immunodeficiency virus (HIV)-positive persons before antiretroviral therapy (ART) initiation to the costs of ART provision to misdiagnosed HIV-negative persons. Savings from averted unnecessary ART costs were greater than retesting costs within 1 year using assumptions representative of HIV testing performance in programmatic settings. Countries should implement re-testing before ART initiation.

KEYWORDS:

HIV testing; antiretroviral treatment; cost-benefit analysis; misdiagnosis

PMID:
28444206
PMCID:
PMC5850410
DOI:
10.1093/cid/cix341
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Silverchair Information Systems Icon for PubMed Central
Loading ...
Support Center